CISSOID S.A. specializes in manufacturing high-temperature semiconductor solutions tailored for power management, power conversion, and signal conditioning in extreme environments. The company offers a range of products, including voltage regulators, voltage references, power switches, diodes, transistors, and high-voltage silicon carbide power modules. Their integrated circuits are designed to operate reliably in temperatures ranging from -55°C to +225°C, with testing extending from -200°C to +300°C. CISSOID's offerings also include mixed signal ICs, such as analog-to-digital converters and amplifiers, as well as high-temperature packaging and electronic systems design services. The company serves various markets, including oil and gas, aerospace, industrial, and automotive sectors, through a network of distributors and representatives across multiple regions, including Asia-Pacific, Europe, and the Americas. Established in 2000 and based in Mont Saint Guibert, Belgium, CISSOID has developed a reputation for reliability through its extensive experience in silicon technologies and high-temperature applications.
VIRIDAXIS
Series B in 2007
Viridaxis SA is a biotechnology company based in Charleroi, Belgium, specializing in the development of biological solutions for horticulturalists and farmers. Founded in 2004 as a spin-off from Louvain Catholic University, the company focuses on the mass production of beneficial insects, particularly parasitoids, to combat crop pests. Utilizing innovative technology, Viridaxis produces environmentally friendly products that serve as alternatives to toxic insecticides, employing biopolymer capsules filled with powdered crustacean and algae extracts. The company supplies its products to both Belgian and multinational companies in the agricultural sector, while expanding its research and development activities to enhance production capacity and develop new offerings.
Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA. Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).